The company expired its plan on July 20, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.31 CNY | -0.36% | -5.34% | +0.26% |
May. 09 | Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License | MT |
Apr. 26 | Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.26% | 2.76B | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B |
- Stock Market
- Equities
- 000403 Stock
- News Pacific Shuanglin Bio-pharmacy Co., LTD
- Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback announced on September 1, 2022 has expired with 1,968,378 shares, representing 0.27% for CNY 40.1 million.